Pharmafile Logo
Pharmafocus logo
Advanced Search

CAR-T

Showing 15 posts of 59 posts found.

scotland

Gilead’s CAR-T therapy Yescarta rejected for NHS use in Scotland

February 12, 2019
Manufacturing and Production, Sales and Marketing CAR-T, Cancer, Gilead, NHS, Scotland, Yescarta, kite pharma

It’s bad news for Scottish patients living with aggressive forms of non-Hodgkin lymphoma (NHL) as it emerges that the Scottish …

News
kymriah

Novartis’ CAR-T therapy Kymriah gets NICE green light in diffuse large B-cell lymphoma

February 1, 2019
Medical Communications, Sales and Marketing CAR-T, Cancer, Kymriah, NICE, Novartis, lymphoma, pharma

NICE has announced another momentous decision for lymphoma patients in England and Wales:, recommending Novartis’ chimeric antigen receptor T cell …

News
novartis_window

Canada Health approves Novartis’ CAR-T therapy Kymriah

January 18, 2019
Medical Communications CAR T, CAR-T, Canada, Cancer, Kymriah, Novartis, oncology

Health Canada has approved Novartis’ CAR-T therapy Kymriah for use in paediatric and young adult patients aged between three and …

News
takeda_usa_pharmaceuticals_u

Takeda unveils three new discovery and development collaborations in immuno-oncology

January 4, 2019
Medical Communications, Research and Development CAR-T, Crescendo Biologics, Memorial Sloan Kettering Cancer Center, Noile-Immune, Takeda, pharma

Takeda has revealed that it is set to bolster its novel immuno-oncology portfolio with three new research collaborations. The Japanese …

News

Merck KGaA hands over CAR-T therapy business to Intrexon in deal worth $175 million

December 20, 2018
Business Services, Medical Communications, Sales and Marketing CAR T, CAR-T, Cancer, Germany, Intrexon, Merck KGaA, darmstadt, oncology

German pharma firm Merck KGaA has agreed to hand over its CAR-T therapy business to US company Intrexon in a …

News
gilead-sciences

Gilead’s CAR-T therapy Yescarta shows two-year response duration in large B-cell lymphoma

December 3, 2018
Research and Development, Sales and Marketing ASH 2-18, CAR-T, Cancer, Gilead, Yescarta, leukaemia, pharma

Gilead has gone head to head with Novartis at the American Society of Hematology (ASH) Annual Meeting 2018, meeting the …

News

Kymriah to be made available in UK for paediatric leukaemia patients via Cancer Drugs Fund

November 15, 2018
Sales and Marketing CAR-T, Cancer, Cancer Drugs Fund, Kymriah, NHS, NICE, leukaemia, pharma

NICE has announced its recommendation that Novartis’ CAR-T cell therapy Kymriah (tisagenlecleucel) be made available in the treatment of relapsed …

News
acute_lymphoblastic_leukaemia_smear

20 year old man died after leukaemia cell was accidently mixed into CAR T therapy

October 2, 2018
Manufacturing and Production CAR T, CAR-T, Cancer, Kymriah, Novartis, leukaemia, oncology

A 20 year old man died after a single leukaemia cell accidentally ended up in a batch of cells that …

News
novartis_window

Novartis strike $40m deal with Chinese firm Cellular Biomedicine

September 28, 2018
Medical Communications CAR T, CAR-T, China, Kymriah, Novartis, cellular biomedicine, prc

Swiss multinational Novartis have paired up with Chinese drugmaker Cellular Biomedicine (CBMG) in order to manufacture CAR-T therapy Kymriah in …

News
white-blood-cell-543471_1920

NICE decision could limit future development of CAR T therapies; Evelyn Warner comments on NICE’s decision making process

September 25, 2018
Research and Development CAR T, CAR-T, Cancer, Duff and Phelps, Kymriah, access, oncology, pricing

Lack of access to CAR T therapies in the United Kingdom could hinder the development of effective personalised cancer treatments, …

News
kymriah

NICE rejects CAR-T therapy Kymriah for DLBCL in adults

September 19, 2018
Research and Development CAR T, CAR-T, Kymriah, NICE, Novartis, leukaemia

The National Institute for health and Care Excellence (NICE) has rejected Novartis’ CAR-T therapy Kymriah for use in adults with …

News

Novartis’ CAR T therapy Kymriah to become available on the NHS

September 5, 2018
Research and Development CAR T, CAR-T, Gilead, Kymriah, NHS, Novartis

Novartis’ Kymriah is set to become the first CAR T therapy to become available on the NHS after it was …

News
novartis_mit_us

Novartis to create 450 new jobs at Aargau site after Kymriah thumbs up

August 29, 2018
Research and Development CAR T, CAR-T, Jobs, Kymriah, Novartis

Swiss multinational Novartis is set to create up to 450 new jobs following the investment of 90 million Swiss Francs …

News
european_commission_web

Novartis’ Kymriah & Gilead’s Yescarta become first EU-approved CAR T therapies

August 28, 2018
Manufacturing and Production, Sales and Marketing CAR T, CAR-T, Cancer, EU, Gilead, Kymriah, Novartis, UK, Yescarta, blood cancer, pharma

Almost one full year since the treatment was given a “historic” approval in the US, Novartis’ CAR T therapy Kymriah …

News
kymriah

CHMP recommends Novartis’ CAR-T therapy Kymriah for EU approval

July 5, 2018
Sales and Marketing CAR-T, CHMP, EMA, EU, Kymriah, Novartis, pharma

The Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Medicines Agency (EMA) approve Novartis’ CAR-T …

News

Latest content

FDA accepts new drug application for Orexo’s opioid overdose medication

November 28, 2023

Arcturus Therapeutics gains FDA ODD for cystic fibrosis treatment

November 28, 2023

Sanofi and Regeneron share results from phase 3 trial for Dupixent as COPD treatment

November 27, 2023

GSK shares results from phase 3 trial for Blenrep as multiple myeloma treatment

November 27, 2023

Alladapt Immunotherapeutics gains FDA Fast Track Designation for ADP101 as food allergy treatment

November 24, 2023